started · updated
Bristol Myers Squibb to invest $2.3bn in Houston biopharma campus
Bristol Myers Squibb has announced a $2.3 billion investment to build a new pharmaceutical manufacturing campus in Houston, Texas. Located at Generation Park, the 600,000-square-foot facility will utilize a modular design to produce various medicines, including biologics, small molecules, and antibody-drug conjugates. The project is expected to create approximately 500 permanent jobs and 2,000 construction-related positions between 2027 and 2030. This initiative is part of the company’s broader $40 billion commitment to expand domestic manufacturing and research in the United States.
In Germany, Eli Lilly is scaling back its investment plans for a new production site in Alzey. The company has reduced its planned expenditure by 50 percent, from an original $2.5 billion, citing German healthcare austerity measures and new legislative burdens. Despite the reduction in scope and potential impact on the original goal of 1,000 jobs, Eli Lilly intends to proceed with the facility's opening, which is scheduled for late 2027. The company has expressed strong criticism of the German government’s healthcare policies, labeling them as austerity measures rather than meaningful reform.
Entities
Alzey · Bristol Myers Squibb · Christopher Boerner · Eli Lilly · Germany · Greg Abbott · Houston
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Eli Lilly will proceed with the opening of its pharmaceutical production facility in Alzey, Germany, despite reduced investment levels. www.volksfreund.de · www.saarbruecker-zeitung.de
- [● 2 SOURCES] The production facility in Alzey is scheduled to open by the end of 2027. www.volksfreund.de · www.saarbruecker-zeitung.de
- [● 2 SOURCES] The original investment plan for the Alzey facility was $2.5 billion (2.16 billion euros). www.volksfreund.de · www.saarbruecker-zeitung.de
- [● 2 SOURCES] The Alzey facility was originally intended to create up to 1,000 specialist jobs. www.volksfreund.de · www.saarbruecker-zeitung.de
- [● 2 SOURCES] Eli Lilly criticized the German government's GKV contribution rate stabilization law, labeling it a 'savings law' rather than a healthcare reform. www.volksfreund.de · www.saarbruecker-zeitung.de
- [● 2 SOURCES] The company has reduced the remaining scope of the Alzey project by 50 percent compared to original plans. www.volksfreund.de · www.saarbruecker-zeitung.de